The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Patient Derived Xenograft Models Market Research Report 2025
Synopsis
The global Patient Derived Xenograft Models market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Patient Derived Xenograft Models is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Patient Derived Xenograft Models is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Patient Derived Xenograft Models include Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd (China) and Xentech (France), etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Patient Derived Xenograft Models, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Patient Derived Xenograft Models.
Report Scope
The Patient Derived Xenograft Models market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Patient Derived Xenograft Models market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Patient Derived Xenograft Models manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Crown Bioscience Inc. (US)
WuXi AppTec (China)
Champions Oncology (US)
The Jackson Laboratory (US)
ONCODESIGN (France)
Charles River Laboratories International (US)
EPO Berlin-Buch GmBH (Germany)
Shanghai LIDE Biotech Co., Ltd (China)
Xentech (France)
Horizon Discovery Group PLC (UK)
Urolead (France)
Explora BioLabs (US)
Segment by Type
Mice Models
Rat Models
Segment by Application
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Academic & Research Institutions
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Patient Derived Xenograft Models manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Patient Derived Xenograft Models in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Patient Derived Xenograft Models market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Patient Derived Xenograft Models is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Patient Derived Xenograft Models is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Patient Derived Xenograft Models include Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd (China) and Xentech (France), etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Patient Derived Xenograft Models, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Patient Derived Xenograft Models.
Report Scope
The Patient Derived Xenograft Models market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Patient Derived Xenograft Models market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Patient Derived Xenograft Models manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Crown Bioscience Inc. (US)
WuXi AppTec (China)
Champions Oncology (US)
The Jackson Laboratory (US)
ONCODESIGN (France)
Charles River Laboratories International (US)
EPO Berlin-Buch GmBH (Germany)
Shanghai LIDE Biotech Co., Ltd (China)
Xentech (France)
Horizon Discovery Group PLC (UK)
Urolead (France)
Explora BioLabs (US)
Segment by Type
Mice Models
Rat Models
Segment by Application
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Academic & Research Institutions
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Patient Derived Xenograft Models manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Patient Derived Xenograft Models in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Patient Derived Xenograft Models Market Overview
1.1 Product Overview and Scope of Patient Derived Xenograft Models
1.2 Patient Derived Xenograft Models Segment by Type
1.2.1 Global Patient Derived Xenograft Models Market Value Comparison by Type (2024-2030)
1.2.2 Mice Models
1.2.3 Rat Models
1.3 Patient Derived Xenograft Models Segment by Application
1.3.1 Global Patient Derived Xenograft Models Market Value by Application: (2024-2030)
1.3.2 Pharmaceutical & Biotechnology Companies
1.3.3 Contract Research Organizations
1.3.4 Academic & Research Institutions
1.4 Global Patient Derived Xenograft Models Market Size Estimates and Forecasts
1.4.1 Global Patient Derived Xenograft Models Revenue 2019-2030
1.4.2 Global Patient Derived Xenograft Models Sales 2019-2030
1.4.3 Global Patient Derived Xenograft Models Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Patient Derived Xenograft Models Market Competition by Manufacturers
2.1 Global Patient Derived Xenograft Models Sales Market Share by Manufacturers (2019-2024)
2.2 Global Patient Derived Xenograft Models Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Patient Derived Xenograft Models Average Price by Manufacturers (2019-2024)
2.4 Global Patient Derived Xenograft Models Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Patient Derived Xenograft Models, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Patient Derived Xenograft Models, Product Type & Application
2.7 Patient Derived Xenograft Models Market Competitive Situation and Trends
2.7.1 Patient Derived Xenograft Models Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Patient Derived Xenograft Models Players Market Share by Revenue
2.7.3 Global Patient Derived Xenograft Models Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Patient Derived Xenograft Models Retrospective Market Scenario by Region
3.1 Global Patient Derived Xenograft Models Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Patient Derived Xenograft Models Global Patient Derived Xenograft Models Sales by Region: 2019-2030
3.2.1 Global Patient Derived Xenograft Models Sales by Region: 2019-2024
3.2.2 Global Patient Derived Xenograft Models Sales by Region: 2025-2030
3.3 Global Patient Derived Xenograft Models Global Patient Derived Xenograft Models Revenue by Region: 2019-2030
3.3.1 Global Patient Derived Xenograft Models Revenue by Region: 2019-2024
3.3.2 Global Patient Derived Xenograft Models Revenue by Region: 2025-2030
3.4 North America Patient Derived Xenograft Models Market Facts & Figures by Country
3.4.1 North America Patient Derived Xenograft Models Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Patient Derived Xenograft Models Sales by Country (2019-2030)
3.4.3 North America Patient Derived Xenograft Models Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Patient Derived Xenograft Models Market Facts & Figures by Country
3.5.1 Europe Patient Derived Xenograft Models Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Patient Derived Xenograft Models Sales by Country (2019-2030)
3.5.3 Europe Patient Derived Xenograft Models Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Patient Derived Xenograft Models Market Facts & Figures by Country
3.6.1 Asia Pacific Patient Derived Xenograft Models Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Patient Derived Xenograft Models Sales by Country (2019-2030)
3.6.3 Asia Pacific Patient Derived Xenograft Models Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Patient Derived Xenograft Models Market Facts & Figures by Country
3.7.1 Latin America Patient Derived Xenograft Models Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Patient Derived Xenograft Models Sales by Country (2019-2030)
3.7.3 Latin America Patient Derived Xenograft Models Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Patient Derived Xenograft Models Market Facts & Figures by Country
3.8.1 Middle East and Africa Patient Derived Xenograft Models Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Patient Derived Xenograft Models Sales by Country (2019-2030)
3.8.3 Middle East and Africa Patient Derived Xenograft Models Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Patient Derived Xenograft Models Sales by Type (2019-2030)
4.1.1 Global Patient Derived Xenograft Models Sales by Type (2019-2024)
4.1.2 Global Patient Derived Xenograft Models Sales by Type (2025-2030)
4.1.3 Global Patient Derived Xenograft Models Sales Market Share by Type (2019-2030)
4.2 Global Patient Derived Xenograft Models Revenue by Type (2019-2030)
4.2.1 Global Patient Derived Xenograft Models Revenue by Type (2019-2024)
4.2.2 Global Patient Derived Xenograft Models Revenue by Type (2025-2030)
4.2.3 Global Patient Derived Xenograft Models Revenue Market Share by Type (2019-2030)
4.3 Global Patient Derived Xenograft Models Price by Type (2019-2030)
5 Segment by Application
5.1 Global Patient Derived Xenograft Models Sales by Application (2019-2030)
5.1.1 Global Patient Derived Xenograft Models Sales by Application (2019-2024)
5.1.2 Global Patient Derived Xenograft Models Sales by Application (2025-2030)
5.1.3 Global Patient Derived Xenograft Models Sales Market Share by Application (2019-2030)
5.2 Global Patient Derived Xenograft Models Revenue by Application (2019-2030)
5.2.1 Global Patient Derived Xenograft Models Revenue by Application (2019-2024)
5.2.2 Global Patient Derived Xenograft Models Revenue by Application (2025-2030)
5.2.3 Global Patient Derived Xenograft Models Revenue Market Share by Application (2019-2030)
5.3 Global Patient Derived Xenograft Models Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Crown Bioscience Inc. (US)
6.1.1 Crown Bioscience Inc. (US) Corporation Information
6.1.2 Crown Bioscience Inc. (US) Description and Business Overview
6.1.3 Crown Bioscience Inc. (US) Patient Derived Xenograft Models Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Crown Bioscience Inc. (US) Patient Derived Xenograft Models Product Portfolio
6.1.5 Crown Bioscience Inc. (US) Recent Developments/Updates
6.2 WuXi AppTec (China)
6.2.1 WuXi AppTec (China) Corporation Information
6.2.2 WuXi AppTec (China) Description and Business Overview
6.2.3 WuXi AppTec (China) Patient Derived Xenograft Models Sales, Revenue and Gross Margin (2019-2024)
6.2.4 WuXi AppTec (China) Patient Derived Xenograft Models Product Portfolio
6.2.5 WuXi AppTec (China) Recent Developments/Updates
6.3 Champions Oncology (US)
6.3.1 Champions Oncology (US) Corporation Information
6.3.2 Champions Oncology (US) Description and Business Overview
6.3.3 Champions Oncology (US) Patient Derived Xenograft Models Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Champions Oncology (US) Patient Derived Xenograft Models Product Portfolio
6.3.5 Champions Oncology (US) Recent Developments/Updates
6.4 The Jackson Laboratory (US)
6.4.1 The Jackson Laboratory (US) Corporation Information
6.4.2 The Jackson Laboratory (US) Description and Business Overview
6.4.3 The Jackson Laboratory (US) Patient Derived Xenograft Models Sales, Revenue and Gross Margin (2019-2024)
6.4.4 The Jackson Laboratory (US) Patient Derived Xenograft Models Product Portfolio
6.4.5 The Jackson Laboratory (US) Recent Developments/Updates
6.5 ONCODESIGN (France)
6.5.1 ONCODESIGN (France) Corporation Information
6.5.2 ONCODESIGN (France) Description and Business Overview
6.5.3 ONCODESIGN (France) Patient Derived Xenograft Models Sales, Revenue and Gross Margin (2019-2024)
6.5.4 ONCODESIGN (France) Patient Derived Xenograft Models Product Portfolio
6.5.5 ONCODESIGN (France) Recent Developments/Updates
6.6 Charles River Laboratories International (US)
6.6.1 Charles River Laboratories International (US) Corporation Information
6.6.2 Charles River Laboratories International (US) Description and Business Overview
6.6.3 Charles River Laboratories International (US) Patient Derived Xenograft Models Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Charles River Laboratories International (US) Patient Derived Xenograft Models Product Portfolio
6.6.5 Charles River Laboratories International (US) Recent Developments/Updates
6.7 EPO Berlin-Buch GmBH (Germany)
6.6.1 EPO Berlin-Buch GmBH (Germany) Corporation Information
6.6.2 EPO Berlin-Buch GmBH (Germany) Description and Business Overview
6.6.3 EPO Berlin-Buch GmBH (Germany) Patient Derived Xenograft Models Sales, Revenue and Gross Margin (2019-2024)
6.4.4 EPO Berlin-Buch GmBH (Germany) Patient Derived Xenograft Models Product Portfolio
6.7.5 EPO Berlin-Buch GmBH (Germany) Recent Developments/Updates
6.8 Shanghai LIDE Biotech Co., Ltd (China)
6.8.1 Shanghai LIDE Biotech Co., Ltd (China) Corporation Information
6.8.2 Shanghai LIDE Biotech Co., Ltd (China) Description and Business Overview
6.8.3 Shanghai LIDE Biotech Co., Ltd (China) Patient Derived Xenograft Models Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Shanghai LIDE Biotech Co., Ltd (China) Patient Derived Xenograft Models Product Portfolio
6.8.5 Shanghai LIDE Biotech Co., Ltd (China) Recent Developments/Updates
6.9 Xentech (France)
6.9.1 Xentech (France) Corporation Information
6.9.2 Xentech (France) Description and Business Overview
6.9.3 Xentech (France) Patient Derived Xenograft Models Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Xentech (France) Patient Derived Xenograft Models Product Portfolio
6.9.5 Xentech (France) Recent Developments/Updates
6.10 Horizon Discovery Group PLC (UK)
6.10.1 Horizon Discovery Group PLC (UK) Corporation Information
6.10.2 Horizon Discovery Group PLC (UK) Description and Business Overview
6.10.3 Horizon Discovery Group PLC (UK) Patient Derived Xenograft Models Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Horizon Discovery Group PLC (UK) Patient Derived Xenograft Models Product Portfolio
6.10.5 Horizon Discovery Group PLC (UK) Recent Developments/Updates
6.11 Urolead (France)
6.11.1 Urolead (France) Corporation Information
6.11.2 Urolead (France) Patient Derived Xenograft Models Description and Business Overview
6.11.3 Urolead (France) Patient Derived Xenograft Models Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Urolead (France) Patient Derived Xenograft Models Product Portfolio
6.11.5 Urolead (France) Recent Developments/Updates
6.12 Explora BioLabs (US)
6.12.1 Explora BioLabs (US) Corporation Information
6.12.2 Explora BioLabs (US) Patient Derived Xenograft Models Description and Business Overview
6.12.3 Explora BioLabs (US) Patient Derived Xenograft Models Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Explora BioLabs (US) Patient Derived Xenograft Models Product Portfolio
6.12.5 Explora BioLabs (US) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Patient Derived Xenograft Models Industry Chain Analysis
7.2 Patient Derived Xenograft Models Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Patient Derived Xenograft Models Production Mode & Process
7.4 Patient Derived Xenograft Models Sales and Marketing
7.4.1 Patient Derived Xenograft Models Sales Channels
7.4.2 Patient Derived Xenograft Models Distributors
7.5 Patient Derived Xenograft Models Customers
8 Patient Derived Xenograft Models Market Dynamics
8.1 Patient Derived Xenograft Models Industry Trends
8.2 Patient Derived Xenograft Models Market Drivers
8.3 Patient Derived Xenograft Models Market Challenges
8.4 Patient Derived Xenograft Models Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
